Bazarbashi Shouki, Bachour Marwan, Bulbul Muhammad, Alotaibi Mohammed, Jaloudi Mohamed, Jaafar Hassan, Mukherji Deborah, Farah Naim, Alrubai Tahseen, Shamseddine Ali
Section of Medical Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Department of Medical Oncology, El Beyrouni University Hospital, Damascus, Syria.
Crit Rev Oncol Hematol. 2014 Apr;90(1):36-48. doi: 10.1016/j.critrevonc.2013.11.001. Epub 2013 Nov 8.
Although most patients with prostate cancer respond to initial androgen-deprivation therapy, progression to castration-resistant prostate cancer (CRPC) is almost inevitable. In 2004, the docetaxel/prednisone regimen was approved for the management of patients with metastatic CRPC, becoming the standard first-line therapy. Recent advances have also led to an unprecedented number of approved new drugs; thus, providing several treatment options for patients with metastatic CRPC. Five new drugs have received US Food and Drug Administration-approval between 2010 and 2012: sipuleucel-T, an immunotherapeutic agent; cabazitaxel, a novel microtubule inhibitor; abiraterone acetate, a new androgen biosynthesis inhibitor; enzalutamide, a novel androgen receptor inhibitor; and denosumab, a bone-targeting agent. Such drugs are either already marketed or about to be marketed in the Middle East. Data supporting the approval of each of these agents are described in this review, as are recent approaches to the treatment of metastatic CRPC.
尽管大多数前列腺癌患者对初始雄激素剥夺疗法有反应，但几乎不可避免地会进展为去势抵抗性前列腺癌（CRPC）。2004年，多西他赛/泼尼松方案被批准用于治疗转移性CRPC患者，成为标准的一线治疗方法。最近的进展还带来了前所未有的大量获批新药；因此，为转移性CRPC患者提供了多种治疗选择。2010年至2012年间，有五种新药获得了美国食品药品监督管理局的批准：免疫治疗药物西妥昔单抗；新型微管抑制剂卡巴他赛；新型雄激素生物合成抑制剂醋酸阿比特龙；新型雄激素受体抑制剂恩杂鲁胺；以及骨靶向药物地诺单抗。这些药物要么已经在中东上市，要么即将在中东上市。本综述描述了支持每种药物获批的数据，以及转移性CRPC的最新治疗方法。
